RE: Where''''s the Buyout?Large, my dear fellow, I know your heart is in the right place and pumping ferociously but do you really think that Pfizer or Merck are going to allow RVX to get away? I can't see Pfizer giving up on the future of Lipitor. All they need to know is that NexVas has a halfVas chance of working and they'll bite. They have the Esperion team and its research to point the way for them. They know how it all works and they know the odds for success. That may turn out to be the biggest single value of Esperion for Pfizer. I can't see them giving up billions of Lipitor revenue forever when, for a couple of billion, they may lock in hundreds of billions in revenue with NexVas.
And there is absolutely nothing pointing to any date or specific timeframe for a buyout. It seems to be imminent, maybe Monday, maybe late this year, whenever.
And a partnership-type of deal? I simply can't see a bid that is a partnership-type of deal winning the prize. Why would the insiders go for it? They can raise the money for Phases I and II, no problem. Why set a price in a partnership deal and get no cash in the shareholders' pockets when they likely would get far more in a buyout after Phase II? A partnership and waiting for Phase II could take much the same amount of time to put cash in the shareholders' pockets from a buyout. There's no advantage in a partnership for anybody if the perceived risk in NexVas is slight. I suppose there are different types of partnership deals but it would have to be a blockbuster.
This is an offer for the pharmas to buy RVX at a discount before it's 100% proven. One can only infer from this that the RVX science, the failure of other CVD therapies, the short time frame to market for NexVas and broader CVD research all point to a strong likelihood of success for NexVas and thus its early sale. The scientists at RVX are the top in the CVD business. They know the value of NexVas because they fully understand its context.
Buyout
Pfizer or Merck
This year
And the green grass grows all around...